Ads
related to: survival food companies
Search results
Actuate Therapeutics (ACTU) to Raise $50 Million in IPO
ETF DAILY NEWS· 1 day agoActuate Therapeutics (ACTU) plans to raise $50 million in an initial public offering on the week of...
Working in ‘hellfire’: Gig workers bear the brunt of India’s heatwave
Al Jazeera· 6 days agoTo support his family, in 2018 the 26-year-old moved from Bihar to New Delhi to work as a delivery...
Costco makes major change customers will notice right away
TheStreet.com· 2 days agoWhen is the last time you enjoyed a good, quality trip to the grocery store? If your answer was...
The Shoebill Stork: One Freaky and Formidable Bird
HowStuffWorks via Yahoo News· 3 days agoBiochemically like a heron and anatomically similar to a pelican, the shoebill stork has been called "Monsterface" and even "Death Pelican." But wait...
State Fair of Texas shooting victim sues companies involved in security, suspected gunman |...
Texarkana Gazette· 1 day agoA woman who was one of three people wounded in a shooting at the State Fair of Texas last year is...
At Cannes, the ad industry contemplates its AI future with a mix of hope and fear
Fortune· 3 days agoAs with those in other industries, creative agencies want AI—but they want it on their own terms. At Cannes, many of the world’s biggest agencies—WPP, Publicis, Havas, and Dentsu—announced plans ...
Bay Area arts: 11 cool concerts, shows and more to catch this weekend
San Jose Mercury News· 1 day agoFrom a new Steinbeck-themed play in Berkeley to a free circus show and the inaugural Cookbook...
AstraZeneca’s lung cancer drug approved by US FDA for combination chemotherapy treatment | Invezz
Invezz· 4 days agoAstraZeneca, the largest pharmaceutical group in Britain, announced that the U.S. Food and Drug...
Gateway - Quartz
Quartz· 3 days agoNovo Nordisk’s blockbuster diabetes drug Ozempic, known for its weight-loss side effects, can also help patients living chronic kidney disease, per a study funded by the pharmaceutical
New EHA data reveal how badly Gilead's $4.9B bet on CD47 imploded
FierceBiotech· 7 days agoGilead Sciences' abandoned anti-CD47 drug magrolimab was not just ineffective, but could potentially...
